fda glp-1 warning 2025 november Semaglutide: The Drug of Today and a Steppingstone to Tomorrow FDA Sends Warning Letters to

Most patients on semaglutide for obesity reach the 2.4 mg maintenance dose

Foundayo and oral Wegovy have arrived

Purpose of Review: This comprehensive review discusses the adverse effects known today about marijuana, for either medical or recreational use

The association was consistent across alcohol- and non-alcohol-related overdoses and was even stronger among patients not receiving traditional addiction-treatment medications

Metabolic bariatric procedures, such as sleeve gastrectomy, achieve rapid and clinically meaningful weight reduction, often resulting in improved operative exposure and technical conditions for subsequent resection